Dedication in Early Phase Oncology.
To provide optimized solutions.
This shift towards smaller early phase oncology trials is likely to continue. We can develop more targeted and effective treatments to test in smaller trials; ultimately leading to better outcomes for cancer patients. However, there are ample challenges like slow recruitment, logistic inconveniences, and a limited number of available KOLs.
As a specialized contract research organizations for Early Phase Oncology, we help improve the odds of success by providing expertise and services throughout the clinical trial process. Our experts are an extension of your team, offering immediate support aligning with your operations.
Oncology Trials in a Shifting Economical & Geopolitical Landscape
Join our experts and learn about global tendencies in oncology clinical trials and how to adapt to them.
The right combination of experience, facilities, and access to patients to accelerate oncology research.
Experience in Early Phase Oncology
Our distinctive combination of experience across indications and unparalleled access to patients in Eastern Europe make us a bespoke partner for your next Early Phase Oncology trial. Over the last years our clinical trial professionals supported over various oncology programs and many novel therapies throughout their careers. Applying their science and risk-based approach for oncology studies results in the early identification of potential challenges and helps devise the right strategy and solution to prevent setbacks later during regulatory submission
Completed or ongoing Oncology Trials
Start-up / Submission Projects
Oncology Patients Recruited
Colleagues Experience in Oncology
Early Phase Oncology Insights
In the last few years, a major breakthrough in cancer research has occurred: early phase oncology trials. This type of trial is designed to test whether a new drug has any adverse effects on people and also provides anecdotal evidence that it might be efficacious....
For all clinical trials, it is crucial that the potential benefits of a medicinal product are determined, while monitoring any potential side effects. However, for early-phase oncology trials, the extensive monitoring of adverse events (AEs) is essential, considering...
The difficulties of recruiting in clinical trials, and particularly cancer patients in their early stages, can significantly obstruct the development of innovative treatments. There is an undeniable increase in demand for Early Phase Clinical studies in patients to...